Skip to content
Fast Company Executive Board

The Fast Company Executive Board is a private, fee-based network of influential leaders, experts, executives, and entrepreneurs who share their insights with our audience.

The real first step to AI-powered pharma compliance

Before unleashing AI agents on validation work, pharma companies should solve a more fundamental problem.

[Photo: Getty Images]

Profile photo of Nagesh Nama

CEO · xLM Continuous Intelligence

Every pharmaceutical company knows the pain. A routine software change—an update to a manufacturing system, a patch to a lab application—triggers weeks of compliance work. Teams chase documents across a dozen platforms. They copy data into spreadsheets, take screenshots as proof, and stitch together approval trails from email threads. By the time they validate the change, months have passed and the next change is already waiting.

The industry is buzzing about AI agents that could automate this work. But here’s what most companies miss: You can’t hand the keys to an AI agent when the information it needs is scattered across 20 different systems, locked behind inconsistent permissions, and organized by tribal knowledge that lives in people’s heads.

The real first step isn’t buying an AI tool. It’s building the foundation that makes AI possible.

THE HIDDEN TAX OF SCATTERED INFORMATION

In a typical pharma company, the information needed to validate a single software change lives in multiple places. Change requests sit in one system. Standard operating procedures live in another. Approved specifications are buried in a document vault. Source code is in a developer repository. Training records are in a learning platform. Quality incidents are tracked somewhere else entirely.

Validation teams bridge these gaps the old-fashioned way: copying links into spreadsheets, manually re-entering data, taking screenshots as evidence, and using email chains as approval records. It works—barely—but it introduces a problem that no amount of effort can fix. Two equally skilled people can assess the same change and arrive at different conclusions, simply because they found different information or interpreted incomplete records differently.

That inconsistency isn’t a people problem. It’s an infrastructure problem.

ONE LAYER TO CONNECT THEM ALL

The solution is a unifying content layer—think of it as a central nervous system for compliance information. It doesn’t replace the systems companies already use. Instead, it connects to them, pulling information from wherever it lives and making it searchable, governed, and ready for action.

This layer does two things at once. First, it maintains its own repository for compliance-ready documents and derived knowledge. Second, it reaches into existing systems—enterprise resource planning, quality management, manufacturing execution, development tools, and more—to retrieve what’s needed on demand.

But connecting information is only half the challenge. The moment you pull content together in a regulated industry, you inherit the enterprise’s biggest risk: governance.

GOVERNANCE ISN’T A FEATURE—IT’S THE WHOLE POINT

In pharma, the ability to prove what happened, when, and by whom isn’t optional—it’s the difference between passing and failing a regulatory inspection. So this content layer must enforce access controls, retention policies, audit trails, and approval workflows as information is retrieved and used, not after the fact.

This is the line between AI that summarizes documents and AI that can participate in regulated operations. Without governance built into the foundation, any AI capability layered on top will be a liability, not an asset.

FROM DOCUMENT HUNTS TO DECISION WORKFLOWS

Once a company has unified, governed access to its compliance information, something remarkable becomes possible. Validation teams—and eventually AI agents—can assemble full context on demand: what system is affected, which procedures apply, what’s already been validated, what the proposed change impacts, what risks exist, and what evidence is needed for release.

Consider this concrete example. Today, when a change request is filed, a validation professional spends days hunting down impacted requirements, related test scripts, prior assessments, and approval histories. With a governed content foundation, an AI agent could pull that all together in minutes—proposing an impact assessment grounded in historical evidence, drafting test updates, flagging traceability gaps, and assembling an inspection-ready audit package. The human reviewer would then focus on judgment calls rather than data gathering.

That’s not automation for speed. It’s automation for consistency, defensibility, and scale.

THE ORGANIZATION THAT LEARNS

There’s a deeper advantage that emerges over time. When every workflow draws from the same governed information base, outcomes stop depending on which person happens to be assigned. The same context is available to every process, every time. And with built-in feedback loops—tracking which risk assessments were accepted, which evidence passed review, which deviations occurred—the system continuously improves without drifting out of compliance.

The frontier of pharma compliance isn’t a single AI model or a clever chatbot. It’s a new operating system for validation—built on information that is unified, governed, and ready for intelligent execution. The companies that build this foundation now will define how the industry operates in the next decade. Those that wait will be playing catch-up with their competitors and their regulators.

Nagesh Nama is CEO of xLM Continuous Intelligence.